Cala Health secured $50 million in growth capital to expand commercial access to the Cala kIQ System, an FDA-cleared wearable device that delivers personalized peripheral nerve stimulation to reduce hand tremors in essential tremor and Parkinson's disease. The device represents a shift toward precision, at-home neuromodulation therapy that addresses motor control dysfunction without systemic medication.
Key Points
- FDA-cleared wearable delivers individualized nerve stimulation based on measured tremor patterns
- Funding enables scaling of U.S. commercial operations and patient access infrastructure
- Therapy addresses essential tremor and Parkinson's disease through targeted peripheral neuromodulati
Longevity Analysis
Tremor severity correlates with falls, functional decline, and quality-of-life deterioration in aging populations, particularly those with neurodegenerative conditions. Precision neuromodulation devices that operate without systemic pharmacology reduce the burden of polypharmacy and its associated cognitive and metabolic effects. Wider access to such targeted therapies addresses both the symptomatic management of neurological dysfunction and the upstream reduction of medication-related interference in aging systems. The at-home delivery model reduces clinical dependency and supports sustained adherence, critical factors in whether patients actually implement therapies consistently enough to derive measurable benefit.
Original published by Longevity.Technology.